Clinical trial
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With…
NCT00282347 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00282347 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis |
| Acronym | LUNAR |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Nephritis |
| Intervention type | Drug |
| Interventions | Rituximab, Placebo, Mycophenolate mofetil, Methylprednisolone, Diphenhydramine, Acetaminophen, Prednisone |
| Enrollment | 144 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2013 |
| First posted | Jan 26, 2006 |
| Last update posted | Jan 15, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: